Kent is a brand of inexpensive cigarettes aimed at a mass audience of smokers. The brand’s products are presented in a wide range of varieties.

Kent cigarettes delight smokers with a pronounced mild character. The taste has a balance between astringency, sweetness and pungent intonations. The thick smoke strikes with a sophisticated tobacco aroma. The manufacturer affixes a digital marking to the name of the cigarettes. The designations indicate the strength level of the product.

The Kent cigarettes maker is going to develop the COVID-19 vaccine.
The British American Tobacco has made great strides in developing a coronavirus vaccine. Production of the drug is expected to begin in June. Experts predict the growth of the company’s shares.

One of the world’s largest tobacco corporations, British American Tobacco, has taken on the development of a vaccine against the COVID-19 coronavirus. It announced this on Wednesday on the website. Looks like that the Kent cigarettes manufacturer plans to promote Kent cigarettes by this way. Maybe, the Kent cigarettes will even be reprocessed to contain anti-COvid stuff. We shall see.

The vaccine is being developed by a subsidiary of the cigarette manufacturer, Kentucky BioProcessing, which specializes in biotechnology. In 2014, it helped develop an experimental drug for the treatment of Ebola.

To obtain the vaccine, the company’s specialists used the latest technology. They cloned part of the coronavirus’s genetic sequence and injected it into tobacco plants, which produced what is called an antigen. This substance helps the body develop immunity against the virus.

The drug is now undergoing preclinical trials. The company said that if testing is successful, then starting in June it will be possible to produce from 1 to 3 million doses of vaccine per week.

“Vaccine development is challenging work, but we believe we have made a significant breakthrough with our technology platform for tobacco plants,” said British American Tobacco Research Director.

The World Health Organization data indicate that plant-based vaccines can be produced cheaply and in very large quantities. The likelihood that they contain harmful substances is much less compared to traditionally developed vaccines, found out in CNN.

The Credit Suisse analysts are optimistic about the prospects for British American Tobacco.